Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal JA (2015) Global cancer statistics, 2012. CA: A Cancer J Clin 65:87–108. doi: 10.3322/caac.21262

Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399):1907–1917. doi: 10.1016/S0140-6736(03)14964-1

Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390. doi: 10.1056/NEJMoa0708857

Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34. doi: 10.1016/S1470-2045(08)70285-7

Cheng AL, Kang YK, Lin DY et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31(32):4067–4075. doi: 10.1200/JCO.2012.45.8372

Johnson PJ, Qin S, Park JW et al (2013) Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31(28):3517–3524. doi: 10.1200/JCO.2012.48.4410

Cainap C, Qin S, Huang WT et al (2015) Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33(2):172–179. doi: 10.1200/JCO.2013.54.3298

Zhu AX, Rosmorduc O, Evans TR et al (2015) SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33(6):559–566. doi: 10.1200/JCO.2013.53.7746

Abou-Alfa GK, Niedzwieski D, Knox JJ et al (2016) Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). J Clin Oncol 34(4S):192–192

Llovet JM, Decaens T, Raoul JL et al (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509–3516. doi: 10.1200/JCO.2012.47.3009

Zhu AX, Kudo M, Assenat E et al (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312:57–67. doi: 10.1001/jama.2014.7189

Zhu AX, Park JO, Ryoo BY et al (2015) Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomized, double-blind, multicentre, phase 3 trial. Lancet Oncol 16:859–870. doi: 10.1016/S1470-2045(15)00050-9

Bruix J, Qin S, Merle P et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 389(10064):56–66. doi: 10.1016/S0140-6736(16)32453-9

Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer;129(1):245–255. doi: 10.1002/ijc.25864

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. doi: 10.1055/s-0030-1247132

Bruix J, Tak WY, Gasbarrini A et al (2013) Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49(16):3412–3419. doi: 10.1016/j.ejca.2013.05.028

Drug safety labeling changes. US food and drug administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203085s007lbl.pdf . Accessed on 23 May 2017

Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10(3):445–447

de’ Angelis N, Landi F, Nencioni M et al (2016) Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation. Prog Transplant 26(4):348–355. doi: 10.1177/1526924816664083

Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M (2012) High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int 25(11):1158–1164. doi: 10.1111/j.1432-2277.2012.01540.x

Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM (1999) Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 19(4):511–514

Finn RS (2017) Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial. J Clin Oncol 35(4S):344–344. doi: 10.1200/JCO.2017.35.4_suppl.344

Belum VR, Wu S, Lacouture ME (2013) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs 31(4):1078–1086. doi: 10.1007/s10637-013-9977-0

Grothey A, Sobrero AF, Siena S et al (2013) Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study. J Clin Oncol 31:3637–3637. doi: 10.1200/jco.2013.31.15_suppl.3637

Mross K, Frost A, Steinbild S et al (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18(9):2658–2667. doi: 10.1158/1078-0432.CCR-11-1900

Ducreux M, Öhler L, Scheithauer W et al (2017) Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: an interim analysis (IA) from the prospective, observational CORRELATE study. J Clin Oncol 35(4S):700–700. doi: 10.1200/JCO.2017.35.4_suppl.700